BETA CAROTENE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C40H56
Molecular Weight	536.8726
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	9
Charge	0

SHOW SMILES / InChI

SMILES

CC(\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)CCCC2(C)C

InChI

InChIKey=OENHQHLEOONYIE-JLTXGRSLSA-N

InChI=1S/C40H56/c1-31(19-13-21-33(3)25-27-37-35(5)23-15-29-39(37,7)8)17-11-12-18-32(2)20-14-22-34(4)26-28-38-36(6)24-16-30-40(38,9)10/h11-14,17-22,25-28H,15-16,23-24,29-30H2,1-10H3/b12-11+,19-13+,20-14+,27-25+,28-26+,31-17+,32-18+,33-21+,34-22+

HIDE SMILES / InChI

Molecular Formula	C40H56
Molecular Weight	536.8726
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	9
Optical Activity	NONE

Description

Beta-carotene is found in many foods and is sold as a dietary supplement. Beta-carotene is a carotenoid, weak antioxidant; precursor of vitamin A, which is essential for vision and growth. Used to reduce the severity of photosensitivity reactions in patients with erythropoietic protoporphyria (EPP). Has been used in high-dose antioxidant supplements containing ascorbic acid and vitamin E with zinc in high-risk patients with age-related macular degeneration. Beta-carotene is also used to decrease asthma symptoms caused by exercise; to prevent certain cancers, heart disease, cataracts; and to treat AIDS, alcoholism, Alzheimer’s disease, depression, epilepsy, headache, heartburn, high blood pressure, infertility, Parkinson’s disease, rheumatoid arthritis, schizophrenia, and skin disorders including psoriasis and vitiligo.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
free radicals 4	Blocker 537
singlet excited oxygen 1	Modulator 828
POU domain, class 5, transcription factor 1 1	Inhibitor 8,297
Protein delta homolog 1 1	Inhibitor 8,297
Hypoxia-inducible factor 1-alpha 10	Inhibitor 8,297

Conditions

Condition	Modality	Highest Phase	Product
Macular degeneration 4	Primary	Phase III 656	Unknown
Erythropoietic protoporphyria 2	Primary	Approved 8,429	SOLATENE
Neuroblastoma 25	Primary	Basic research	Unknown
Head and neck cancer 50	Preventing	Phase III 656	Unknown
Cardiovascular diseases 71	Preventing	Phase II 1,132	Unknown
Maternal mortality, fetal loss, or infant mortality 1	Preventing	Phase III 656	Unknown
Retinitis pigmentosa 10	Primary	Phase III 656	Unknown
Psoriasis 84	Primary	Phase III 656	Unknown
Chronic pancreatitis 3	Palliative	Phase III 656	Unknown

PubMed

Show entries

Title	Date	PubMed
Β-carotene inhibits neuroblastoma tumorigenesis by regulating cell differentiation and cancer cell stemness.	2014 Aug 8	25019987

Showing 1 to 1 of 1 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

For Erythropoietic Protoporphyria 0–300 mg (50,000–500,000 IU beta carotene) daily; For Macular Degeneration 15 mg daily in combination with ascorbic acid 500 mg daily, vitamin E 400 units daily, and zinc (as zinc oxide) 80 mg daily, with copper (as cupric oxide) 2 mg daily

Route of Administration: Oral

In Vitro Use Guide

In vitro evaluation of BC (Beta-carotene) on rat H9c2 cells showed that the agent significantly improved vitality of these cells in a dose range of 2.5–10 uM.